Trial Profile

A single ascending dose(SAD) and single ascending dose (MAD ) phase I trial of TP-6076 in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Nov 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TP 6076 (Primary)
Indications Bacterial infections
Focus Adverse reactions; First in man; Pharmacokinetics

Most Recent Events

05 Oct 2018 Results of the multiple ascending dose study presented at the IDWeek 2018.
19 Sep 2018 According to Tetraphase Pharmaceuticals media release, data from this trial will be presented at the Infectious Disease Society of Americas (IDSA) Infectious Disease Week (IDWeek) 2018.
02 Aug 2018 According to a Tetraphase Pharmaceuticals media release, the company anticipates completing MAD potion in 2H 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com